EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Biological Evaluation of Thieno[3,2- d ]pyrimidine Derivatives as the First Bifunctional PI3Kδ Isoform Selective/Bromodomain and Extra-Terminal Inhibitors

Kai Ran, Jiu-Hong Huang, Yong Li iD, Yimei Zhang, Hao Hu, Zhengyu Wang, Dian-Yong Tang iD, Hong-Yu Li iD, Zhi-Gang Xu, Zhong-Zhu Chen iD

Journal of Medicinal Chemistry · 13.02.2025 · 68 (3) · 3260-3281

DOI: 10.1021/acs.jmedchem.4c02478 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 24.01.2025. Verfasst von Kai Ran und 9 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, National & Local Joint Engineering Research Center of Targeted and Innovative Therapeutics, IATTI, Chongqing University of Arts …. Hauptthemen laut MEDLINE: Pyrimidines, Drug Design, Class I Phosphatidylinositol 3-Kinases, Antineoplastic Agents. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: Chongqing Municipal Education Commission, Chongqing University of Arts and Sciences, Natural Science Foundation of Chongqing Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The concomitant inhibition of PI3Kδ and bromodomain and extra-terminal (BET) that exerts a synergistic effect on the B-cell receptor signaling pathway provides a new strategy for the treatment of aggressive diffuse large B-cell lymphoma (DLBCL). Herein, a merged pharmacophore strategy was utilized to discover a series of thieno[3,2-d]pyrimidine derivatives as the first-in-class bifunctional PI3Kδ-BET inhibitors. Through optimization, a highly potent compound (10b) was identified to possess excellent and balanced activities against PI3Kδ [inhibitory concentration (IC50) = 112 ± 8 nM] and BRD4-BD1 (IC50 = 19 ± 1 nM) and exhibited strong antiproliferative activities in DLBCL cells. Notably, this compound demonstrated good PI3Kδ selectivity over other kinases with minimal cytotoxicity in normal cells. Moreover, 10b has a good oral pharmacokinetic profile in mice and achieves outstanding antitumor activity in the SU-DHL-6 xenograft model. Taken together, these results indicate that targeting PI3Kδ and BET with a bifunctional inhibitor is a promising strategy to treat DLBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrimidinesDrug DesignClass I Phosphatidylinositol 3-KinasesAntineoplastic AgentsHumansAnimalsMiceCell Line, TumorStructure-Activity RelationshipLymphoma, Large B-Cell, DiffuseCell ProliferationPhosphoinositide-3 Kinase InhibitorsProtein Kinase InhibitorsXenograft Model Antitumor AssaysMolecular Docking Simulation

Substanzen

PyrimidinesClass I Phosphatidylinositol 3-KinasesAntineoplastic AgentsPIK3CD protein, humanPhosphoinositide-3 Kinase InhibitorsProtein Kinase Inhibitorsthieno(2,3-d)pyrimidine

Autor:innen und Institutionen

  • College of Pharmacy, National & Local Joint Engineering Research Center of Targeted and Innovative Therapeutics, IATTI, Chongqing University of Arts and Sciences, Chongqing 402160, China.
  • Department of Pharmacology, College of Medicine, University of Texas Health San Antonio, San Antonio, Texas 78229, United States.

ORCID-Profile: Yong Li, Dian-Yong Tang, Hong-Yu Li, Zhong-Zhu Chen

Förderung

  • Chongqing Municipal Education Commission
  • Chongqing University of Arts and Sciences
  • Natural Science Foundation of Chongqing Municipality

Zitieren

APA

Ran, K., Huang, J. H., Li, Y., Zhang, Y., Hu, H., Wang, Z., Tang, D. Y., Li, H. Y., Xu, Z. G., & Chen, Z. Z. (2025). Design, Synthesis, and Biological Evaluation of Thieno[3,2- d ]pyrimidine Derivatives as the First Bifunctional PI3Kδ Isoform Selective/Bromodomain and Extra-Terminal Inhibitors. Journal of Medicinal Chemistry, 68(3), 3260-3281. https://doi.org/10.1021/acs.jmedchem.4c02478

Vancouver

Ran K, Huang JH, Li Y, Zhang Y, Hu H, Wang Z, et al. Design, Synthesis, and Biological Evaluation of Thieno[3,2- d ]pyrimidine Derivatives as the First Bifunctional PI3Kδ Isoform Selective/Bromodomain and Extra-Terminal Inhibitors. Journal of Medicinal Chemistry. 2025;68(3):3260-3281. doi:10.1021/acs.jmedchem.4c02478

BibTeX
@article{Ran2025,
  author = {Ran, Kai and Huang, Jiu-Hong and Li, Yong and Zhang, Yimei and Hu, Hao and Wang, Zhengyu and Tang, Dian-Yong and Li, Hong-Yu and Xu, Zhi-Gang and Chen, Zhong-Zhu},
  title = {Design, Synthesis, and Biological Evaluation of Thieno[3,2- d ]pyrimidine Derivatives as the First Bifunctional PI3Kδ Isoform Selective/Bromodomain and Extra-Terminal Inhibitors},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {3},
  pages = {3260--3281},
  doi = {10.1021/acs.jmedchem.4c02478}
}
Kostenlos starten →